Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

NCT04223635 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate Hepatic Impairment

Interventions

DRUG: Pexidartinib

Sponsor

Daiichi Sankyo